{"id":"xeloxa","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Hand-foot skin reaction"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Myelosuppression"},{"rate":"10-20","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"XELOXA typically refers to a capecitabine-based chemotherapy combination used in digestive tract cancers. Capecitabine is a prodrug that is converted to 5-fluorouracil (5-FU) in tumor tissue, where it inhibits thymidylate synthase and disrupts DNA and RNA synthesis. This leads to apoptosis of cancer cells, particularly those with high proliferation rates.","oneSentence":"XELOXA is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:03.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT00197873","phase":"NA","title":"Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"2005-09","conditions":"Colorectal Cancer","enrollment":84},{"nctId":"NCT00335595","phase":"PHASE3","title":"Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2006-07","conditions":"Colorectal Cancer","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XELOXA","genericName":"XELOXA","companyName":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","companyId":"spanish-cooperative-group-for-the-treatment-of-digestive-tumours-ttd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XELOXA is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis to kill rapidly dividing cancer cells. Used for Colorectal cancer, Gastric cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}